Pfizer Inc.(NYSE:PFE) Inc is now officially a partner to the Milner Therapeutics Consortium according to The Milner Therapeutics Institute. The duo’s collaboration will facilitate the professional transfer of materials between industry and academia. Thanks to the fact that the Consortium is regarded a matchmaker between pharmaceutical companies and researchers. The move will, in addition, enhance distribution of funds for partnering opportunities in Cambridge.

For a while now, the Consortium has been campaigning for proper development of the drugs. To that effect, it has embraced the duty of bringing together the drug development capability of pharmaceutical companies. They are expected to put their expertise together and push forward the speedy exchange of resources and information.

The role of the Consortium’s Innovation Board

One of the greatest roles for the Consortium is bringing on board innovation that will grow the industry. It is also responsible for management of the considered direction of company partners who can either work as individuals with academics or through mutual activities. This, in fact, helps the acceleration of drug development. In this case Vice President, External R&D Innovation at Pfizer, Dr. Ron Newbold becomes part of the Milner Innovation Board.  Others will include representatives from Astex, AstraZeneca, and GlaxoSmithKline. Remember the Innovation Board is also entrusted with collaborative activities.

In appreciation of the collaboration, founder, and director of the Milner Therapeutics Institute, Prof Tony Kouzarides commented, “We are building the foundations for a world-leading ecosystem for therapeutics research around the Milner Therapeutics Institute. We are delighted that Pfizer has joined the Consortium to develop mutually-beneficial collaborations with Cambridge academics and the Milner Therapeutics Institute.”

Milner Therapeutics Institute is seeking to make a difference to therapies

Kouzarides is of the opinion that their collaboration with Pfizer will bring more advanced disease understanding. These are the same sentiments that Newbold is holding onto as he also looks into a deeper commitment in the Cambridge ecosystem. He is also excited at the upcoming opportunity of being able to meet many world-class scientists, thanks to the strong academic and biotech community in the UK.

Meanwhile, Pfizer’s was trading at $31.70 a fall of $0.33 or 1.03%.